Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to try to define the highest doses of temsirolimus and
gemcitabine that can be used safely in combination to treat advanced pancreatic cancer.
Gemcitabine is a standard chemotherapy used for the treatment of pancreatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brigham and Women's Hospital Dana-Farber Cancer Institute Wyeth is now a wholly owned subsidiary of Pfizer